AstraZeneca and Oxford’s COVID-19 vaccine shows promising results
Category: #headlines  | By Nikita Chaurasia  | Date: 2020-10-27 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca and Oxford’s COVID-19 vaccine shows promising results
  • The vaccine AZD1222 has reportedly triggered lower adverse response among elderly participants.
     
  • Oxford’s and AstraZeneca’s COVID-19 vaccine could be the first candidate to receive a regulatory approval.

According to reliable sources, Oxford University’s COVID-19 vaccine candidate has displayed favorable results after producing immune response among both younger as well as adult participants.

The vaccine AZD1222, which is developed through a collaboration between University of Oxford and British pharmaceutical giant AstraZeneca plc, has reportedly also triggered lower adverse response among elderly participants, which is not the case with other vaccines under trial.

Sources with knowledge of the matter stated that the positive results emerged in data regarding safety & immune responses of study participants during Oxford’s phase II trials. The data included results of British volunteers of the age group 56-69 as well as that of over 70, which is likely to be formally published in the upcoming weeks.

According to the University of Oxford, the recently acquired results mark a milestone and provide assurance that the vaccine is not only safe to use, but also induces a strong immune response among individuals of all age groups.

It is to be noted that Oxford University and AstraZeneca have been conducting trials of their potential COVID-19 vaccine for months across the globe.

The potential vaccine could be a game changer in the battle against the COVID-19 pandemic, which has killed over 1.15 million people world over. In fact, Oxford’s and AstraZeneca’s COVID-19 vaccine could be the first candidate to receive a regulatory approval along with potential candidates like BioNtech as well as Pfizer.

Matt Hancock, British Health Secretary, was reported saying that although the vaccine is not ready yet, the department is preparing for essential logistics required for a possible roll out, mostly during the first half of the year 2021.

Meanwhile, staff at a major hospital in London have been informed to be prepared to receive the first batch of AstraZeneca and Oxford’s COVID-19 vaccine in first week of November, claimed sources with relevant information.

Source Credits –

https://www.reuters.com/article/us-health-coronavirus-astrazeneca-vaccin/vaccine-hopes-rise-as-oxford-jab-prompts-immune-response-among-old-as-well-as-young-adults-idUSKBN27B0IV

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...